![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CSRNP3 |
Gene summary for CSRNP3 |
![]() |
Gene information | Species | Human | Gene symbol | CSRNP3 | Gene ID | 80034 |
Gene name | cysteine and serine rich nuclear protein 3 | |
Gene Alias | FAM130A2 | |
Cytomap | 2q24.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8WYN3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80034 | CSRNP3 | HCC1_Meng | Human | Liver | HCC | 2.94e-13 | -5.33e-03 | 0.0246 |
80034 | CSRNP3 | HCC1 | Human | Liver | HCC | 3.92e-14 | 1.39e+00 | 0.5336 |
80034 | CSRNP3 | S014 | Human | Liver | HCC | 4.34e-06 | 3.99e-01 | 0.2254 |
80034 | CSRNP3 | S016 | Human | Liver | HCC | 3.43e-17 | 6.91e-01 | 0.2243 |
80034 | CSRNP3 | HTA12-23-1 | Human | Pancreas | PDAC | 1.06e-11 | 9.56e-01 | 0.3405 |
80034 | CSRNP3 | HTA12-25-1 | Human | Pancreas | PDAC | 8.60e-13 | 9.93e-01 | 0.313 |
80034 | CSRNP3 | HTA12-26-1 | Human | Pancreas | PDAC | 4.51e-30 | 1.24e+00 | 0.3728 |
80034 | CSRNP3 | HTA12-29-1 | Human | Pancreas | PDAC | 4.69e-52 | 1.08e+00 | 0.3722 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CSRNP3 | SNV | Missense_Mutation | novel | c.217N>C | p.Tyr73His | p.Y73H | Q8WYN3 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
CSRNP3 | SNV | Missense_Mutation | novel | c.1394T>G | p.Leu465Arg | p.L465R | Q8WYN3 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.74) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSRNP3 | SNV | Missense_Mutation | rs543669496 | c.1082N>T | p.Thr361Met | p.T361M | Q8WYN3 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSRNP3 | SNV | Missense_Mutation | novel | c.601N>A | p.Glu201Lys | p.E201K | Q8WYN3 | protein_coding | deleterious(0) | benign(0.177) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
CSRNP3 | SNV | Missense_Mutation | rs183252532 | c.1249N>A | p.Ala417Thr | p.A417T | Q8WYN3 | protein_coding | tolerated(0.43) | benign(0) | TCGA-EO-A3AZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSRNP3 | SNV | Missense_Mutation | c.189G>T | p.Lys63Asn | p.K63N | Q8WYN3 | protein_coding | tolerated(0.14) | possibly_damaging(0.752) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
CSRNP3 | SNV | Missense_Mutation | novel | c.104A>G | p.Asp35Gly | p.D35G | Q8WYN3 | protein_coding | tolerated(0.09) | probably_damaging(0.998) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
CSRNP3 | SNV | Missense_Mutation | novel | c.551C>T | p.Ala184Val | p.A184V | Q8WYN3 | protein_coding | deleterious(0.05) | probably_damaging(0.996) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
CSRNP3 | insertion | Frame_Shift_Ins | novel | c.915_916insTTTCCCCCAA | p.Ala306PhefsTer16 | p.A306Ffs*16 | Q8WYN3 | protein_coding | TCGA-A5-A0R8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
CSRNP3 | insertion | In_Frame_Ins | novel | c.1296_1297insCCTTGGCAA | p.Ser432_Ser433insProTrpGln | p.S432_S433insPWQ | Q8WYN3 | protein_coding | TCGA-B5-A11F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
80034 | CSRNP3 | NA | Bisphosphonates |
Page: 1 |